Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JK06 |
| Synonyms | |
| Therapy Description |
JK06 is an antibody-drug conjugate (ADC) comprising a quadrivalent biparatopic antibody targeting TPBG (5T4) linked to monomethyl auristatin E, which potentially binds to TPBG (5T4) expressed on tumor and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 5447). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JK06 | JK-06|JK 06 | JK06 is an antibody-drug conjugate (ADC) comprising a quadrivalent biparatopic antibody targeting TPBG (5T4) linked to monomethyl auristatin E, which potentially binds to TPBG (5T4) expressed on tumor and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 5447). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06667960 | Phase Ib/II | JK06 | Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer | Recruiting | ESP | BEL | 0 |